Search - tctmd.com

Displaying 661 - 680 of 1248

Sort: Relevancy | Date

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Todd Neale

October 03, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

News Conference News TCT 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Michael O'Riordan

September 27, 2019

News Conference News TCT 2019

From Ceiling Suspension to Eye-Tracking: Innovation Continues for Cath Lab Radiation Protection

Yael L. Maxwell

September 25, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Daily News

CMS Weighs Reimbursement for Out-of-Hospital Coronary Interventions

Caitlin E. Cox

September 20, 2019

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Industry News

Reduce Fmr Study Shows Cardiac Dimensions’ Carillon® System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure

September 12, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

ESC Updates Guidance on Management of Acute Pulmonary Embolism

Todd Neale

September 06, 2019

News Conference News ESC 2019

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Shelley Wood

September 04, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

News Daily News

VA Medical Centers’ Quality Measures for TAVR Pay Off

Caitlin E. Cox

August 30, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

Shelley Wood

August 30, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Protracted Opioid Use Not Uncommon After Cardiothoracic Surgery

Caitlin E. Cox

August 23, 2019

Advertisement

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

TCTMD’s Top 10 Most Popular Stories for September 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

From Ceiling Suspension to Eye-Tracking: Innovation Continues for Cath Lab Radiation Protection

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

CMS Weighs Reimbursement for Out-of-Hospital Coronary Interventions

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

Reduce Fmr Study Shows Cardiac Dimensions’ Carillon® System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

ESC Updates Guidance on Management of Acute Pulmonary Embolism

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

VA Medical Centers’ Quality Measures for TAVR Pay Off

TCTMD’s Top 10 Most Popular Stories for August 2019

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Protracted Opioid Use Not Uncommon After Cardiothoracic Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content